Search - tctmd.com

Displaying 381 - 400 of 458

Sort: Relevancy | Date

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Yael L. Maxwell

March 09, 2013

News Daily News

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Yael L. Maxwell

March 09, 2013

Presentation

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Presenter: Jessica L. Mega

March 04, 2013

News Daily News

ROCKET AF Analysis Looks at Stroke Risk After Stopping Anticoagulation

February 04, 2013

News Daily News

El ROCKET AF Analiza el Riesgo de ACV tras Interrumpir la Anticoagulación

February 04, 2013

Presentation

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

Presenter: Manesh R. Patel

February 03, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

Presentation AHA 2012

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Presenter: Saurav Chatterjee

November 04, 2012

News Conference News TCT 2012

Stroke Prevention Strategies Discussed

October 26, 2012

Presentation TCT 2012

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Presenter: C. Michael Gibson

October 25, 2012

Presentation TCT 2012

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Presenter: C. Michael Gibson

October 24, 2012

Advertisement

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

ROCKET AF Analysis Looks at Stroke Risk After Stopping Anticoagulation

El ROCKET AF Analiza el Riesgo de ACV tras Interrumpir la Anticoagulación

Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular A-fib

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Rivaroxaban Use is Associated with Reduced Risk of Myocardial Infarction- Insights from a Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

Stroke Prevention Strategies Discussed

Should Rivaroxaban Be Used in STEMI Patients, and Does Choice of ADP Antagonist (with Rivaroxaban) Matter?

Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content